Aliski William												
Form 4 November 08, 201	18											
FORM 4									OMB APPROVAL			
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB Number:	3235-0287		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. <i>See</i> Instruction 1(b).	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								Expires: Estimated a burden hour response	rs per		
(Print or Type Respon	nses)											
1			2. Issuer Name <b>and</b> Ticker or Trading Symbol Ultragenyx Pharmaceutical Inc. [RARE]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Mon			3. Date of (Month/Da 11/08/20	-	ansaction			X_ Director 10% Owner Officer (give title Other (specify below) below)				
	Street)		4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting				
		(in)						Person				
· • / · · ·		Cip)		e I - Non-D			-	uired, Disposed of		-		
			Date, if	3. Transactic Code (Instr. 8) Code V	(Instr. 3,	sposed 4 and (A) or	d of (D)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Common 11/0 Stock	08/2018			S <u>(1)</u>	6,000	D	\$ 55.67	96,350	I	By trust (2)		
Common Stock								72,610	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## Edgar Filing: Aliski William - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Amou Unde Secur	rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Reporting Owner Name / Address		Relationships						
		Director	10% Owner	Officer	Other			
Aliski William C/O ULTRAGENYX PHARMACEUTIC 60 LEVERONI COURT NOVATO, CA 94949	AL INC.	X						
Signatures								
/s/ Ruben A. Garcia, attorney-in-fact	11/08/2018	8						
<u>**</u> Signature of Reporting Person	Date							

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sale reported on this Form 4 was effected pursuant to a trading plan adopted by the Reporting Person's trust pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- (2) These shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse and nephew are trustees of the trust.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.